BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PARI's eFlow Wins Good Design Award


1/3/2007 3:00:41 PM

MONTEREY, Calif., Jan. 3 /PRNewswire/ -- PARI's eFlow was awarded a 2006 GOOD DESIGN Award for medical equipment by The Chicago Athenaeum: Museum of Architecture and Design earlier this month. This is the second design award eFlow has won this year, following the Medical Design Excellence Award granted in April. eFlow is a handheld, electronic nebulizer that dramatically reduces treatment time for aerosolized medications targeting the lungs.

"We are extremely pleased to be recognized by the design community for the modern styling of eFlow. In addition to vastly improving the technology so that patients have faster inhaled medication therapies, we spent a lot of time on the look and feel. eFlow is light, fits in the palm of your hand, and is very comfortable and easy to use. These awards are icing on the cake, and they show that quality and design go hand in hand," said Thomas Gallem, Head of Product Design at PARI.

eFlow uses a perforated, vibrating membrane that enables extremely efficient aerosolization of liquid medications. Compared to other nebulizer systems, eFlow can produce aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode of operation, small size, lightweight, and battery use, eFlow helps reduce the burden of taking daily inhaled treatments.

Due to its efficiency, eFlow is licensed to pharmaceutical companies during drug development and for later commercialization, so that drug and device are optimized together for the final product. This customization is currently being utilized in the development of new and improved treatments for cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD), alpha-1-antitrypsin deficiency, lung transplant rejection, respiratory syncytial virus infection (RSV), and for systemic drug delivery via the lungs.

eFlow was developed by PARI and incorporates TouchSpray Technology licensed from the Technology Partnership, Cambridge, UK. eFlow's modern, sleek shape was designed by Eckstein Design in Munich, Germany. Eckstein designs medical equipment, consumer, and industrial goods and has also designed PARI's portable and desktop compressor/nebulizer systems.

About GOOD DESIGN Awards

Founded in Chicago in 1950 by architects Eero Saarinen, Charles and Ray Eames, and Edgar Kaufmann, Jr., the GOOD DESIGN Awards bestow international recognition upon the world's most prominent designers and manufacturers for advancing innovative product concepts and for stretching the envelope beyond what is considered basic product design. GOOD DESIGN is organized by The Chicago Athenaeum: Museum of Architecture and Design. Additional information online at www.chi-athenaeum.org .

About PARI

PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's primary focus is to provide patients with innovative products and services that help control disease. PARI also develops pharmaceutical drug products for pulmonary and nasal administration as liquid aerosols and already has several clinical development programs ongoing, either partnered or on its own. PARI is headquartered in Starnberg, Germany, with a major presence in the United States and offices in Japan, United Kingdom, Russia, and China.

PARI

CONTACT: Kirsten Ayars, +1-805-452-7909, or Geoff Hunziker,+1-831-372-3580, both of PARI



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES